Skip to main
  1. Stocks
  2. Phathom Pharmaceuticals
  3. Forecast
PHAT

Phathom Pharmaceuticals (PHAT) Stock Forecast & Price Target

Phathom Pharmaceuticals (PHAT) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Phathom Pharmaceuticals is supported by a differentiated, first-in-class P-CAB profile in VOQUEZNA, whose clinical data show rapid, durable acid suppression and strong efficacy in erosive GERD and H. pylori, including 93% healing versus 85% for lansoprazole and superior results in severe disease. The commercial thesis is strengthened by a large addressable GERD market, >80% commercial coverage, and management’s tighter GI-focused strategy after the May 2025 restructuring, with sales rising from $55MM in 2024 to 2026 guidance of $310–325MM and EBITDA profitability expected in 2026. Further upside could come from continued access improvement, a potential 2032 exclusivity runway, and pipeline expansion in EoE, where positive Phase 2 data could add another meaningful growth vector.

Bears say

Phathom Pharmaceuticals is facing a fundamentally challenged setup because VOQUEZNA’s growth has already run below the launch trajectory, with physicians still encountering access friction in a highly genericized GERD and NERD market where PPI step edits remain standard. While the company expects about $131MM of CY27 EBITDA, the thesis is pressured by modest 1H26 progress, no clear near-term upside to estimates, and a potential competing P-CAB launch in early 2027 that could dilute share and pricing. The outlook is further weakened by the exclusion of EoE from the model absent compelling 4Q26 data, plus meaningful balance-sheet risk from the $300MM secured Hercules term loan and restrictive cash covenants.

Phathom Pharmaceuticals (PHAT) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Phathom Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Phathom Pharmaceuticals (PHAT) Analyst Forecast & Price Prediction

Get the latest Phathom Pharmaceuticals (PHAT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Phathom Pharmaceuticals (PHAT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Phathom Pharmaceuticals (PHAT) Forecast

Analysts have given Phathom Pharmaceuticals (PHAT) a Buy based on their latest research and market trends.

According to 5 analysts, Phathom Pharmaceuticals (PHAT) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Phathom Pharmaceuticals (PHAT)


Phathom Pharmaceuticals (PHAT) Analyst Forecast & Price Prediction

Get the latest Phathom Pharmaceuticals (PHAT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Phathom Pharmaceuticals (PHAT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PHAT stock data and trends